Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture +3 more
wiley +1 more source
Granulocyte colony-stimulating factor protects against acute systemic alphavirus disease in a type I IFN-dependent manner. [PDF]
Hameed M +5 more
europepmc +1 more source
Regenerative Endodontics in Teeth With Irreversible Pulpitis: A Scoping Review
ABSTRACT Introduction Regenerative endodontic procedures (REPs) have been widely used to manage a range of pulpal pathologies, particularly in immature permanent teeth. The development of bioactive calcium silicate–based materials has led to a paradigm shift in vital pulp therapy (VPT) and REPs.
Mahmoud Torabinejad +2 more
wiley +1 more source
Effects of different granulocyte colony stimulating factor regimens on patients with euploid embryo transfer in recurrent implantation failure. [PDF]
Karaosmanoglu O +6 more
europepmc +1 more source
When to consider an inborn error of immunity: clues for physicians
Abstract The term inborn errors of immunity (IEIs) refers to the rapidly expanding group of genetic disorders causing dysregulation of the immune system. With improved genetic testing in recent years, the number of defined IEIs and their range of phenotypic presentations has grown vastly, with more than 550 IEIs now described.
Meera Thangarajah, Lucinda J. Berglund
wiley +1 more source
Literature review analysis of aortitis induced by granulocyte-colony stimulating factor. [PDF]
Zhao T, Xu H.
europepmc +1 more source
Deep and disseminated dermatophytosis in immunocompromised populations—A systematic review
Dermatophyte infections of the dermis and subcutaneous tissue (i.e. deep dermatophytosis)—associated with secondary complications including pseudomycetoma and systemic dissemination—affect vulnerable populations with primary or acquired immunodeficiencies.
Aditya K. Gupta +5 more
wiley +1 more source
Polyethylene glycol-conjugated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) primary prophylaxis significantly reduces the duration of neutropenia in non-Hodgkin's lymphoma patients treated with chemotherapy: a randomised trial (NCT05834751). [PDF]
Wang B +8 more
europepmc +1 more source
Anumigilimab, a novel anti‐G‐CSF receptor antibody, was investigated in a phase 1b trial involving 39 patients with hidradenitis suppurativa or palmoplantar pustulosis. No serious safety concerns related to anumigilimab were noted, and PK and PD were dose dependent.
Johannes S. Kern +14 more
wiley +1 more source

